期刊文献+

慢性心力衰竭综合治疗的临床观察

Chronic heart failure complex therapy clinical observation
原文传递
导出
摘要 目的:观察综合疗法治疗慢性心力衰竭的疗效.方法:将100例慢性心力衰竭患者随机分为传统治疗组和综合治疗组各50例.传统治疗组以强心、利尿、扩张血管治疗为主 综合治疗组在应用利尿药、洋地黄制剂病情稳定后,逐渐加用卡托普利、倍他乐克及螺内酯,比较两组疗效.结果:传统治疗组总有效率为94%,综合治疗组总有效率为84%,两组比较,差异有统计学意义(P〈0.05).结论:综合治疗组疗效明显优于传统治疗组,具有良好的应用前景. Objective: Observation synthesis therapy treatment chronic heart failure curative effect. Methods:Divides into the traditional treatment group and complex therapy group each 50 examples stochastically 100 example chronic heart failure patient. Traditional treatment group by strong heart, diuresis, expansion blood vessel treatment primarily; Complex therapy group after application diuretics, digitalis preparation condition stable, adds gradually with Catto Pulley,time of his Le Ke and the spiral lactone,compared with two groups of curative effects. Results:Traditional treatment group total effectiveness is 94%, complex therapy group total effectiveness is 84%, two groups of comparisons, the difference has statistics significance (P〈0.05). Conclusion:The complex therapy group curative effect surpasses the traditional treatment group obviously, has the good application prospect.
作者 王淑芳
出处 《按摩与康复医学》 2010年第36期96-96,共1页 Chinese Manipulation and Rehabilitation Medicine
关键词 慢性心力衰竭 综合治疗 疗效 Chronic heart failure Complex therapy Curative effect
  • 相关文献

参考文献2

二级参考文献20

  • 1Kalon KL,Joan LP, William BK. The epidemiology of heart failure: the Framingham study. J Am Coll Cardiol, 1993,22 (Suppl A):6A-13A.
  • 2Hung YT, Cheug NT, Ip S. Epidemiology of heart failure in Hong Kong,1997. Hong Kong Med J, 2000,6:159-162.
  • 3Packer M, Coats AJS, Fowler MB, et al. For the Carvedilol Prospective Randomized Cumulative Survival Study Group. Effects of carvedilol on survival in severe chronic heart failure. N Engl J Med, 2001, 344:1651-1658.
  • 4Remme WJ, Swedberg K. Guidelines for the diagnosis and treatment of chronic heart failure. Task force for the diagnosis and treatment of chronic heart failure, European Society of Cardiology. Eur Heart J, 2001, 22: 1527-1561.
  • 5Hunt HA, Baker DW, Chin MH, et al. ACC/AHA Guidelines for the Evaluation and Management of Chronic Heart Failure in the Adult: Executive Summary A Report of the American College of Cardiology/American Heart Association Task Force on Practice Guidelines (Committee to Revise the 1995 Guidelines for the Evaluation and Management of Heart Failure). Developed in collaboration with the international society for heart and lung transplantation. Circulation, 2001, 104:2996-3007.
  • 6MITROV1C V, WILLENBROCK R, MIRIC M, et al. Acute and 3-month treatment effects of candesartan cilexetil on hemodynamics, neurohormones, and clinical symptoms in patients with congestive heart failure[J]. Am Heart J, 2003, 145(3): E14.
  • 7SAKATA Y, YAMAMOTO K, MASUYAMA T, et al. Ventricular production of natriuretic peptides and ventricular structural remodeling in hypertensive heart-failure[J]. J Hypertens, 2001,19(10): 1905-1912.
  • 8FENTON C, SCOTT LJ. Candesartan cilexetil: a review of its use in the management of chronic heart failure[J]. Drugs, 2005,65(4): 537-558.
  • 9MATSUMORI A. Efficacy and safety of oral candesartan cilexetil in patients with congestive heart failure[J]. Eur J Heart Fail, 2003,5(5) : 669-677.
  • 10GLEITER CH, MORIKE KE. Clinical pharmacokinetics of candesartan[J]. Clin Pharmacokinet, 2002, 41 ( 1 ) : 7-17.

共引文献365

相关作者

内容加载中请稍等...

相关机构

内容加载中请稍等...

相关主题

内容加载中请稍等...

浏览历史

内容加载中请稍等...
;
使用帮助 返回顶部